Detalles de la búsqueda
1.
Withdrawal of Immunomodulators or TNF Antagonists in Patients With Inflammatory Bowel Diseases in Remission on Combination Therapy: A Systematic Review and Meta-analysis.
Clin Gastroenterol Hepatol
; 22(1): 22-33.e6, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37716619
2.
Drug Levels Associated With Optimal Discrimination Between Remission and Nonremission and Comparison of Antibody Assays During First Year of Stable Infliximab Maintenance Therapy in Inflammatory Bowel Disease.
Ther Drug Monit
; 44(2): 290-300, 2022 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34387220
3.
A systematic monitoring approach to biologic therapies in inflammatory bowel disease: patients' and physicians' preferences and adherence.
Scand J Gastroenterol
; 57(3): 274-281, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34779308
4.
Fatigue is a systemic extraintestinal disease manifestation largely independent of disease activity, chronicity, and nutritional deficiencies in inflammatory bowel disease on biologics.
Scand J Gastroenterol
; 57(9): 1051-1057, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35412932
5.
Treatment to target in patients with inflammatory bowel disease. What is the evidence?
Scand J Gastroenterol
; 55(5): 528-536, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-32503364
6.
Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease.
Scand J Gastroenterol
; 55(8): 884-890, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32631131
7.
Absence of Relationship Between Crohn's Disease Activity Index or C-Reactive Protein and Infliximab Exposure Calls for Objective Crohn's Disease Activity Measures for the Evaluation of Treatment Effects at Treatment Failure.
Ther Drug Monit
; 41(2): 235-242, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30883516
8.
Inflammatory bowel disease with primary sclerosing cholangitis: A Danish population-based cohort study 1977-2011.
Liver Int
; 38(3): 532-541, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28796371
9.
Outcome of continued infliximab therapy in Crohn's disease patients with response but without remission after one year of infliximab - a retrospective cohort study.
Scand J Gastroenterol
; 53(8): 930-937, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-29987951
10.
Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease.
Dig Dis Sci
; 63(6): 1583-1591, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29564674
11.
Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease.
BMC Med
; 15(1): 184, 2017 10 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-29032767
12.
Time Course and Clinical Implications of Development of Antibodies Against Adalimumab in Patients With Inflammatory Bowel Disease.
J Clin Gastroenterol
; 50(6): 483-9, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-26166141
13.
Challenges and opportunities for IBD drug development: from early stage to regulatory approval.
Gut
; 69(7): 1157-1161, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32179569
14.
Systematic Information to Health-Care Professionals about Vaccination Guidelines Improves Adherence in Patients With Inflammatory Bowel Disease in Anti-TNFα Therapy.
Am J Gastroenterol
; 110(11): 1526-32, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26032156
15.
Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn's Disease Patients Failing Infliximab.
Dig Dis Sci
; 60(9): 2762-70, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25673037
16.
Biosimilars for Management of Crohn Disease.
Ann Intern Med
; 170(2): 129-130, 2019 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30535358
17.
Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial.
Gut
; 63(6): 919-27, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23878167
18.
Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial.
Am J Gastroenterol
; 109(7): 1055-64, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24796769
19.
Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn's disease.
Ther Drug Monit
; 35(4): 530-8, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23765033
20.
Exploring disease-related and treatment-related issues and concerns experienced by adults with spondyloarthritis, inflammatory bowel disease and psoriasis to identify unmet needs: a qualitative clinical concept mapping study.
BMJ Open
; 13(12): e071586, 2023 12 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-38081674